Neuroprotection for treatment of glaucoma in adults

Abstract

Background Glaucoma is a heterogeneous group of conditions involving progressive damage to the optic nerve, deterioration of retinal ganglion cells, and ultimately visual field loss. It is a leading cause of blindness worldwide. Open angle glaucoma (OAG), the most common form of glaucoma, is a chronic condition that may or may not present with increased intraocular pressure (IOP). Neuroprotection for glaucoma refers to any intervention intended to prevent optic nerve damage or cell death. Objectives The objective of this review was to systematically examine the evidence regarding the effectiveness of neuroprotective agents for slowing the progression of OAG in adults compared with no neuroprotective agent, placebo, or other glaucoma treatment. Search methods We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 7), Ovid MEDLINE, Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE Daily (January 1946 to August 2016), Embase (January 1980 to August 2016), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to August 2016), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov), and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 16 August 2016. Selection criteria We included randomised controlled trials (RCTs) in which topical or oral treatments were used for neuroprotection in adults with OAG. Minimum follow-up time was four years. Data collection and analysis Two review authors independently reviewed titles and abstracts from the literature searches. We obtained full-text copies of potentially relevant studies and re-evaluated for inclusion. Two review authors independently extracted data related to study characteristics, risk of bias, and outcomes. We identified one trial for this review, thus we performed no meta-analysis. Two studies comparing memantine to placebo are currently awaiting classification until study investigators provide additional study details. We documented reasons for excluding studies from the review. Main results We included one multicenter RCT of adults with low-pressure glaucoma (Low-pressure Glaucoma Treatment Study, LoGTS) conducted in the USA. The primary outcome was progression of visual field loss after four years of treatment with either brimonidine or timolol. Of the 190 adults enrolled in the study, the investigators excluded 12 (6.3%) after randomization; 77 participants (40.5%) did not complete four years of follow-up. The rate of attrition was unbalanced between groups with more participants dropping out of the brimonidine group (55%) than the timolol group (29%). Of those remaining in the study at four years, participants assigned to brimonidine showed less progression of visual field loss than participants assigned to tim...

Memantine‐Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma

“…MEM is a neuroprotective agent approved by the FDA for the treatment of AD that acts by inhibiting NMDA‐induced glutamate excitotoxicity; it may also prevent RGC death in glaucoma . Although preclinical data previously suggested a potential clinical benefit of orally administered MEM for the treatment of glaucoma, the efficacy of this route of MEM administration is limited, and may have contributed to the results of a phase III clinical trial in glaucoma which apparently failed in meeting its primary endpoint …”

Conduct and reporting of citation searching in Cochrane systematic reviews: A cross‐sectional study

“…19 Although no reviews reported using a citation index for backward citation searching, only three reviews (2%) explicitly stated that a manual approach was used. 38,48,59 Reports of citation searching in some reviews used phrases suggestive of manual checking rather than a citation index, such as "we scanned the reference lists of relevant studies," but we felt this was still not fully transparent. Hence, these are recorded as manual (assumed) in Table 4.…”

Nanotechnology for Medical and Surgical Glaucoma Therapy—A Review

“…There are numerous ongoing studies aimed at offering neuroprotective or neuroregenerative treatments [16], but clinical trials have been unsuccessful in the past at demonstrating their effectiveness in preventing glaucoma progression [43][44][45]. One of the main challenges of this approach has been how to allow access of the drug to the back of the eye, where the optic nerve and RGCs reside.…”